Recent

% | $
Quotes you view appear here for quick access.

ImmunoGen, Inc. Message Board

biobottom 2 posts  |  Last Activity: Sep 21, 2015 2:38 PM Member since: Jan 29, 1999
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Morgan Stanley Downgrade

    by hubris13 Sep 21, 2015 12:15 PM
    biobottom biobottom Sep 21, 2015 2:38 PM Flag

    ...near-term mean limited newsflow to drive Immunogen shares higher in the near term." (cut and paste courtesy of Patrick Williams of Bezinga, published earlier today in article called:" New Biotech Pair Trade: Infinity Pharma Over ImmunoGen" From me: This is of course a little disheartening, but I added 500 shares to my long position in IMGN. IMGN can also surprise on the upside once and a while, and over the very long term will reach its full potential.

  • Reply to

    Morgan Stanley Downgrade

    by hubris13 Sep 21, 2015 12:15 PM
    biobottom biobottom Sep 21, 2015 2:33 PM Flag

    In the report Morgan Stanley noted that Immunogen’s management plans to study alternative dosing schedules besides adding two “additional cohorts with IMGN853 as part of the PhI protocol (n=40 in combination with steroid eye drops and n=20 with pre/post treatment biopsy) in addition to the already enrolled n=40 expansion cohort.”
    This indicates that the company is trying to expand the therapeutic window and that “safety/tolerability remains a risk.” Harrison mentioned that this slows down the approval timing too. The absence of any catalysts in the near-term mean limited newsflow to drive Immunogen shares higher in the near term.In the report Morgan Stanley noted that Immunogen’s management plans to study alternative dosing schedules besides adding two “additional cohorts with IMGN853 as part of the PhI protocol (n=40 in combination with steroid eye drops and n=20 with pre/post treatment biopsy) in addition to the already enrolled n=40 expansion cohort.”
    This indicates that the company is trying to expand the therapeutic window and that “safety/tolerability remains a risk.” Harrison mentioned that this slows down the approval timing too. The absence of any catalysts in the

    Sentiment: Buy

IMGN
3.13-0.05(-1.57%)Jun 29 4:00 PMEDT